In July 2026, the European stock market has shown resilience, with the STOXX Europe 600 Index rising by nearly 2% amid easing inflation concerns and a more stable economic outlook. As investors navigate these conditions, growth companies with substantial insider ownership often attract attention due to their potential alignment of interests and commitment to long-term success.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Kuros Biosciences (SWX:KURN) | 26.1% | 58.4% |
| KebNi (OM:KEBNI B) | 11.8% | 90.9% |
| Hacksaw (OM:HACK) | 13.2% | 24.8% |
| Dellia Group (OB:DELIA) | 29.9% | 47.9% |
| CTT Systems (OM:CTT) | 17.4% | 47.1% |
| Clavister Holding AB (publ.) (OM:CLAV) | 20.7% | 73.9% |
| Circus (XTRA:CA1) | 21.9% | 84.4% |
| CD Projekt (WSE:CDR) | 35.2% | 29.7% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 33.7% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 50.2% |
Let's uncover some gems from our specialized screener.
ACS Actividades de Construcción y Servicios (BME:ACS)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: ACS, Actividades de Construcción y Servicios, S.A. is a global construction and services company with a market cap of €31.98 billion.
Operations: ACS generates revenue through several segments, including Cimic (€10.41 billion), Turner (€26.49 billion), Infrastructure (€256.38 million), HQ and Non-Core Activities (€2.57 billion), and Engineering and Construction (€10.68 billion).
Insider Ownership: 14.4%
Return On Equity Forecast: 22% (2029 estimate)
ACS Actividades de Construcción y Servicios is poised for growth, with revenue expected to rise 8.4% annually, outpacing the Spanish market. Despite high debt levels and large one-off items impacting earnings quality, its return on equity is forecast to reach 21.6% in three years. Recent events include a follow-on equity offering raising €679 million and a stock split effective June 29, 2026, which may influence shareholder dynamics without recent insider trading activity noted.
- Get an in-depth perspective on ACS Actividades de Construcción y Servicios' performance by reading our analyst estimates report here.
- Upon reviewing our latest valuation report, ACS Actividades de Construcción y Servicios' share price might be too optimistic.
Lime Technologies (OM:LIME)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Lime Technologies AB (publ) provides SaaS-based CRM solutions in the Nordic region and has a market cap of SEK2.76 billion.
Operations: The company's revenue is primarily derived from selling and implementing CRM software systems, totaling SEK758.87 million.
Insider Ownership: 10.7%
Return On Equity Forecast: 32% (2029 estimate)
Lime Technologies is positioned for growth, with earnings projected to increase by 15.5% annually, surpassing the Swedish market. The company trades at a significant discount to its estimated fair value and has seen substantial insider buying recently, indicating confidence in its prospects. Recent board changes bring experienced leadership focused on software and business development. Despite modest revenue growth of 8.5% annually, Lime's financial performance remains robust with a strong return on equity forecasted at 31.9%.
- Unlock comprehensive insights into our analysis of Lime Technologies stock in this growth report.
- The valuation report we've compiled suggests that Lime Technologies' current price could be quite moderate.
Newron Pharmaceuticals (SWX:NWRN)
Simply Wall St Growth Rating: ★★★★★★
Overview: Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on discovering and developing novel therapies for central and peripheral nervous system diseases in Italy and the United States, with a market cap of CHF250.50 million.
Operations: The company generates its revenue primarily from the research and development of pharmaceutical drugs, amounting to €19.13 million.
Insider Ownership: 10.1%
Return On Equity Forecast: 36% (2028 estimate)
Newron Pharmaceuticals is poised for significant growth, with revenue expected to increase by 38.2% annually, outpacing the Swiss market. The company trades at a substantial discount to its fair value and is forecasted to achieve profitability within three years, indicating strong growth potential. Despite a recent FDA hold on its ENIGMA-TRS 2 study due to safety concerns, Newron continues international trials and works closely with regulators for resolution, showcasing resilience in drug development efforts.
- Take a closer look at Newron Pharmaceuticals' potential here in our earnings growth report.
- Our valuation report unveils the possibility Newron Pharmaceuticals' shares may be trading at a discount.
Where To Now?
- Get an in-depth perspective on all 205 Fast Growing European Companies With High Insider Ownership by using our screener here.
- Looking For Alternative Opportunities? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com